A single dose of the approved Ervebo Ebola vaccine triggers cross-reactive T-cell immune responses against the Bundibugyo ebolavirus in humans, according to a study published in October 2026. The findings offer a potential path forward during the world’s second-largest Ebola outbreak in the Democratic Republic of Congo.
Medical researchers have uncovered new evidence that an existing vaccine developed for one strain of Ebola can provoke immune system activity against an entirely different, un-immunized variant. The research, published in The Lancet Infectious Diseases, centers on the VSV-EBOV vaccine, widely known as Ervebo and manufactured by Merck Sharp & Dohme. While the vaccine is a proven defense against the Zaire ebolavirus, the new findings show it also stimulates T cells capable of recognizing the Bundibugyo ebolavirus.
That recognition comes at a critical juncture in Central Africa. The ongoing outbreak of the Bundibugyo virus in the Democratic Republic of Congo stands as the world’s second-largest ebolavirus epidemic on record. Confirmed cases have surpassed 6,000, and the virus carries a staggering fatality rate of 48 percent. Despite the severity of the crisis, no licensed vaccine specifically targets the Bundibugyo strain.
Mapping Cross-Reactive T Cells After Vaccination
The group included researchers from the German Center for Infection Research, alongside specialists from the University Medical Center Hamburg-Eppendorf and the LMU University Hospital in Munich.
An important step forward in the ongoing Bundibugyo Ebola outbreak in the DRC.70,000 doses of Ervebo have been allocated—20,000 for a Phase 3 trial evaluating protection against Bundibugyo virus and 50,000 for frontline and health workers.We need to protect people today while… https://t.co/3Rrga5yr3K
The collaborative team examined blood samples drawn from 28 days after healthy adults received a single dose of Ervebo. Using multiple sequence alignments, the scientists compared the amino acid sequences of the viral glycoproteins. They discovered that the surface proteins of the Zaire, Bundibugyo, and Sudan viruses share highly conserved regions—stretches of sequence that remain largely identical despite the phylogenetic distance between the pathogens.
Out of 20 vaccinated participants tested at the 28-day mark, 16 exhibited Ebola-glycoprotein-specific T-cell responses. Crucially, 13 participants showed Bundibugyo-reactive T cells, and seven displayed cross-reactivity against the Sudan virus. Most individuals who developed a positive reaction to the Ebola glycoprotein also mounted T-cell activity against the Bundibugyo variant.
Clinical trials designed to test dedicated Bundibugyo vaccines are underway, but regulatory approval and manufacturing scale-up take time. Meanwhile, the epidemic in the Democratic Republic of Congo continues to expand, maintaining its near 50 percent mortality rate. Because dedicated preventatives remain unavailable, the research team suggests that deploying an authorized vaccine off-label or within structured trials could offer a pragmatic stopgap.
Christof Geldmacher said that while the study has limitations due to the small sample size, given the lack of a BDBV-specific vaccine, the research supports systematically evaluating the EBOV vaccine in further clinical trials during the current BDBV outbreak, according to MedLabPortal.
That sentiment was echoed by colleagues at Hamburg-Eppendorf. Researchers emphasized that while the trial cohort of 20 vaccinated volunteers provides a modest sample size, the immunological data clearly demonstrate that the standard Zaire-targeted vaccine wakes up dormant cross-reactive cellular pathways.
Unresolved Questions on Clinical Protection
Proving that an injection provokes a laboratory-measured T-cell response is distinct from proving it prevents disease in a patient. Investigators acknowledge that whether these cross-reactive T cells translate into improved clinical outcomes during a real-world Bundibugyo infection remains unknown.
Past preclinical evaluations in nonhuman primates indicate that T-cell activity plays a mandatory role in achieving vaccine-mediated protection against filoviruses. Yet, translating those animal data into human protection against an emerging variant requires rigorous field evaluation.